-
Innovation Ranking
NewInnovation Ranking – Veru Inc
Veru Inc (Veru) is a biopharmaceutical company that develop novel medicines for the management of breast cancer and prostate cancer. The company is headquartered in United States.
-
Product Insights
NewNet Present Value Model: Veru Inc’s VERU-100
Empower your strategies with our Net Present Value Model: Veru Inc's VERU-100 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Veru Inc’s Enobosarm
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Company Insights
Innovation and Patenting activity of Veru Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Veru Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – MCARH-171 in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MCARH-171 in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MCARH-171 in Relapsed Multiple Myeloma Drug Details: MCARH-171 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TDI-01 in Pneumoconiosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TDI-01 in Pneumoconiosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TDI-01 in Pneumoconiosis Drug Details: TDI-01 is under development for the treatment of...
-
Product Insights
Smallpox – Drugs In Development, 2023
Global Markets Direct’s, ‘Smallpox - Drugs In Development, 2023’, provides an overview of the Smallpox pipeline landscape. The report provides comprehensive information on the therapeutics under development for Smallpox, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Acute Promyelocytic Leukemia – Drugs In Development, 2023
Global Markets Direct’s, ‘Acute Promyelocytic Leukemia - Drugs In Development, 2023’, provides an overview of the Acute Promyelocytic Leukemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acute Promyelocytic Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Muscle Wasting Disorders – Drugs In Development, 2023
Global Markets Direct’s, ‘Muscle Wasting Disorders - Drugs In Development, 2023’, provides an overview of the Muscle Wasting Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Muscle Wasting Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...